Product
Target
Indication
Commercial Rights
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD4059
(RiboGalSTARTM)
FXI
Thrombotic Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD5044
(RiboGalSTARTM)
APOC3
Hypertrigly-
ceridemiaGlobal
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD7022
(RiboGalSTARTM)
PCSK9
Hypercho-
lesterolemiaGlobal
(ex-China) *Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD7007
(RiboGalSTARTM)
C5
Renal Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD2080
(RiboGalSTARTM)
Undisclosed
Renal Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD1119
(RiboGalSTARTM)
Undisclosed
Thrombotic Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD6096
(RiboGalSTARTM)
Undisclosed
Thrombotic Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD4094
(RiboGalSTARTM)
Undisclosed
Dyslipidemia
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
SR122
(RiboGalSTARTM)
Dual Targets
Dyslipidemia
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
-
RBD3103
(RiboPepSTARTM)
Undisclosed
Renal Diseases
Global
Preclinical
IND-Enabling
Phase l
Phase ll
Phase lll
* In December 2023, we granted Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) exclusive rights to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong, and Macau.